| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | KIA; MIB-; MIB-1; PPP1R105 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human MKI67 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于MKI67抗体的代表性文献摘要概览：
1. **《Ki-67 protein: The immaculate deception?》**
- **作者**: Scholzen T, Gerdes J.
- **摘要**: 综述了Ki-67蛋白在细胞增殖中的生物学功能，分析了MKI67抗体(如MIB-1克隆)在检测细胞增殖活性中的应用局限性，强调其在不同组织固定方式和实验条件中的结果变异性。
2. **《Comparison of antibodies for the detection of proliferation-related antigen Ki-67》**
- **作者**: McCarty KS Jr et al.
- **摘要**: 比较了不同克隆号(如MIB-1、SP6)的MKI67抗体在福尔马林固定组织中的染色效果，发现抗体选择及抗原修复方法显著影响肿瘤增殖指数评估的准确性。
3. **《Ki-67 assessment in breast cancer: An update》**
- **作者**: Urruticoechea A et al.
- **摘要**: 探讨MKI67抗体在乳腺癌预后和化疗疗效预测中的临床价值，指出标准化评分阈值缺失是限制其广泛应用的主要挑战。
4. **《Standardization of Ki-67 immunohistochemistry: Guidelines from the International Ki-67 Working Group》**
- **作者**: Enwere EK et al.
- **摘要**: 国际工作组提出MKI67抗体检测的标准化操作流程，涵盖样本处理、抗体选择(如克隆号一致性)及结果判读规范，旨在提高不同研究间的可比性。
The MKI67 antibody targets the Ki-67 protein, a nuclear antigen encoded by the *MKI67* gene, widely recognized as a key marker of cellular proliferation. Discovered in the 1980s, Ki-67 is expressed during all active phases of the cell cycle (G1. S, G2. and mitosis) but is absent in quiescent (G0) cells, making it a reliable indicator of proliferating cells. Its dynamic expression pattern correlates with tumor growth rates, and it has become a critical tool in cancer research and diagnostics.
Antibodies against Ki-67 (e.g., clones MIB-1. SP6) are routinely used in immunohistochemistry (IHC) to assess proliferation indices in tumor specimens. High Ki-67 levels are often associated with aggressive malignancies and poor prognosis in cancers like breast carcinoma, lymphoma, and glioblastoma. However, interpretation can vary due to tissue-specific expression patterns, antibody clone differences, and scoring methodologies. For instance, MIB-1 detects a formalin-resistant epitope, enabling its use in paraffin-embedded samples, while other clones may require fresh tissue.
Clinically, Ki-67 aids in stratifying patients for therapy, such as distinguishing luminal B (high Ki-67) from luminal A breast cancers. Despite its utility, debates persist about standardization, with efforts like the International Ki-67 in Breast Cancer Working Group aiming to harmonize protocols. Ongoing research explores its role beyond proliferation, including potential links to cellular stress and non-proliferative functions.
×
